Skip to main content


Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy OnlineFirst articles

15.06.2018 | Focussed Research Review

Fighting breast cancer stem cells through the immune-targeting of the xCT cystine–glutamate antiporter

Tumor relapse and metastatic spreading act as major hindrances to achieve complete cure of breast cancer. Evidence suggests that cancer stem cells (CSC) would function as a reservoir for the local and distant recurrence of the disease, due to …

09.06.2018 | Commentary

Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab

Lung cancer is the most common malignancy worldwide. Despite significant advances in diagnosis and treatment, mortality rates remain extremely high, close to incidence rates. Several targeted therapies have been recently introduced for the …

05.06.2018 | Original Article

Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT

Ipilimumab is a fully human recombinant monoclonal antibody, which acts by blocking the immune checkpoint pathway involving the CTLA-4. CTLA-4 exerts, when activated, an inhibitory effect on T cells [ 1 ]. Blocking of CTLA-4 by ipilimumab results …

04.06.2018 | Original Article

Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies

The recruitment of T-cells by bispecific antibodies secreted from adoptively transferred, gene-modified autologous cells has shown satisfactory results in preclinical cancer models. Even so, the approach’s translation into the clinic will require …

31.05.2018 | Original Article

Differential regulation of human monocytes and NK cells by antibody-opsonized tumors

The monocyte network is important for therapeutic efficacy of antibody therapies against cancer. One mechanism which monocytes/macrophages use to kill cancer cells is phagocytosis. Using trastuzumab and human breast cancer cell lines as a model …

Aktuelle Ausgaben

Über diese Zeitschrift

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.

In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

  • “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
  • “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT),and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).







Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.